MARKET

CADL

CADL

Candel Therapeutics, Inc.
NASDAQ
8.67
+0.17
+2.00%
After Hours: 8.69 +0.02 +0.23% 16:22 06/09 EDT
OPEN
8.55
PREV CLOSE
8.50
HIGH
8.85
LOW
8.27
VOLUME
1.56M
TURNOVER
--
52 WEEK HIGH
9.57
52 WEEK LOW
4.350
MARKET CAP
635.25M
P/E (TTM)
-8.8687
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CADL last week (0601-0605)?
Weekly Report · 1d ago
Analyst Reiterates Buy Rating on Strengthened Phase 3 Data for Aglatimagene Besadenovec, Maintains $23 Price Target
TipRanks · 06/02 16:45
Candel Publishes Phase 3 Results For Aglatimagene In Treating Prostate Cancer, Notes Improved DFS
NASDAQ · 06/02 15:26
Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene
TipRanks · 06/02 14:27
Candel Therapeutics Announces Lancet Oncology Publication Of Phase 3 Data Showing 30% DFS Improvement For Aglatimagene Besadenovec In Localized Prostate Cancer
Benzinga · 06/02 12:19
Candel Therapeutics says Phase 3 trial shows 30% disease-free survival gain for CAN-2409 in localized prostate cancer
PUBT · 06/02 12:09
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Barchart · 06/02 07:05
Candel Therapeutics grants inducement stock options for 63,000 shares at $8.3 each
PUBT · 06/01 20:08
More
About CADL
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.

Webull offers Candel Therapeutics Inc stock information, including NASDAQ: CADL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CADL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CADL stock methods without spending real money on the virtual paper trading platform.